Jacobson Pharma (HKG:2633) expects its profit from continuing operations to rise over 40% year over year for the year ended March 31, a Monday Hong Kong bourse filing said.
The drugmaker attributed the higher profit mainly to a good performance in the specialty medicines and overall generic drug business, revenue contributions from newly in-licensed products and the launch of new products, and cost controls.